Abstract: Peyronie's disease is a disfiguring and psychologically devastating disease, which continues to pose a significant clinical conundrum to the attending doctor. Many forms of therapy have been trialled but results have been inconsistent at best. Non-surgical therapy revolves around oral, intralesional and shockwave therapies. The focus of this paper is on intralesional agents, their evolution and efficacy of treatments. The mere fact that so many agents have been tried is a testament to the incomplete knowledge that we have with regards to the underlying pathophysiology of the disease. Currently, the only U.S. Food and Drug Administration (FDA) approved agent that has shown fairly consistent results is Clostridium histiolyticum collagenase (Xiaflex TM ), whereas calcium channel blockers and interferons (IFN) remain as offlabel options.
Introduction
Peyronie's disease has been plaguing mankind for ages. This psychologically devastating and deforming condition is characterised by the presence of penile plaques, penile angulation and painful erections, often associated with erectile dysfunction. The exact underlying pathophysiology (1) is still uncertain up to this day; although physicians currently hypothesize that the plaque arises after trauma to the penile bodies, resulting in cytokine mediated activation of fibroblasts and the laying down of collagen within the tunica albuginea.
The symptoms of Peyronie's disease follow a variable clinical course. A fair majority often reports resolution of pain, while patients with penile curvature are split amongst improvement, stabilisation and progression. Mulhall et al. (2) reported in 2006 that of his 246 patients, 89% of them had resolution of pain, while 12% improved, 40% remained stable, and 48% had worsened curvature. In 2007, Grasso et al. (3) followed 110 patients for at least 6 years, and reported 68% of younger patients (<50 years old) versus 31.5% of older patients (>50 years old) experienced progression of penile curvature, with more patients in the older subgroup experiencing resolution of pain (69% vs. 20%). However, this is contradicted by a recent observation study in 2014, when Berookhim et al. (4) reported on 176 men with uniplanar curvature, who opted for conservative management and were followed for >12 months. In his series, 67% experienced no change in penile curvature, 12% improved with a mean of 27° change, and 21% worsened (mean change of angulation of 22°) with those who experienced progression being older and have been experiencing symptoms for a longer period of time. These observations suggest that pain from Peyronie's disease is often self-limiting and resolves over time despite the lack of treatment. However, the clinical course of penile curvature is less predictable, thus justifying the need for treatment to prevent worsening loss of sexual function.
As our understanding of this condition advances, many non-surgical treatment modalities, targeting various parts of the disease process, have been attempted. They consist of oral, intralesional and extra-corporal energy therapies. De Peyronie, himself, was the first to utilise topical mercury and mineral water (Holy water of Bareges) to treat the plaques, eventually reporting efficacy with regular use of mineral water. In 1901, Walsham and Spencer (5) were the first to inject mercury (a prevalent treatment of sexually transmitted diseases then) and iodide directly into penile plaques, attempting to dissolve them. However, not only did these agents prove ineffective, it also led to significant toxic side effects, resulting in its abandonment. Current injectable agents can be broadly categorised into two groups, namely anti-inflammatory/proliferative agents and lytic agents. These agents, their mechanism of action and their common side effects are summarised in Table 1 and Figure 1 . This article aims to review the evolution of the various types of injectable intralesional therapies, and focus on recently published articles, thus summarising the current evidence relating to the efficacy of these injectables agents.
Intralesional steroids
In a 1953 journal of urology article, Bodner et al. (6) reported modest success with the intralesional administration of dexamethasone, reducing both the plaque size and subjective penile pain. Winter et al. (7) again reported in the Journal of Urology in 1975, their results of 21 patients, who received 6 to 10 injections at intervals of 1 for 6 months, where a "high percentage of the cases there occurred a disappearance or decrease in the size of the plaques, pain on erection and discomfort during sexual relations" as well as "a high rate of improvement in the chordee". However, in view of the small numbers, the authors felt that "statistical significance is not believed applicable" and that the results were not significantly different from the expected natural course of Peyronie's disease. Furthermore, the side effects related to the prolonged use of steroids, such as local tissue atrophy, thinning of the overlying penile skin and immunosuppression precluded its use, making it fall out favour over time.
Orgotein
A form of medical grade copper/zinc superoxide dismutase, Orgotein possesses anti-inflammatory properties, and was first utilised in the treatment of inflammatory bladder conditions, such as radiation-induced cystitis as early as 1974. Orgotein exerts its effect through the breakdown of superoxides free radicals to hydrogen peroxide and oxygen molecules, thus reducing inflammation and fibrosis. This led to the hypothesis that direct injections of orgotein into these penile plaques may reduce their sizes and help with pain. Two small scale studies in 1981 showed promise, in which Bartsch et al. (8) showed that his 23 patients had significant reduction of the induration size, pain and penile patient demographics were also reviewed to "predict" response to IFN treatment. However, while this revealed that a penile curvature of <30° was associated with a more than 20% improvement of angular deviation (P<0.001), an absolute angular improvement was similar regardless of the pre-treatment curvature (P=0.41). Contrary to current belief, this paper also revealed that response to IFN therapy was independent of mean duration of disease (<1 vs. (19) reported benefits relating to the improvement of erectile function with each of the aforementioned regimes. However, it is difficult, to say the least, to draw any definitive conclusions due to the lack of a placebo control group in each of these prospective studies. Reported complications of intralesional verapamil were fairly minor, ranging from pain at the injection site, penile bruising, nausea and giddiness. In view of the lack of placebo controlled trials and the only two RCTs producing inconsistent results, the Food and Drug Administration (FDA) has yet to approve the use of verapamil in the treatment of Peyronie's disease. However, the latest AUA guidelines relating to the treatment of Peyronie's disease do not forbid the off-label use of verapamil in a properly pre-counselled patient, after taking into consideration the previous evidence of benefit and the lack of serious adverse events.
Nicardipine
Recent interest in an alternative calcium channel blocker, Nicardipine, has yielded promising results. Soh et al. (26) reported in 2010 a randomised placebo controlled trial involving 74 patients, where a statistically significant reduction in pain (P=0.019), erectile dysfunction (P<0.01) and plaque size (P=0.0004) was seen. The outcome, however, did not reveal statistically significant difference in reduction of penile curvature (P=0.14) between the two groups. This novel calcium channel blocker remains unverified and is currently not recommended for routine use.
Collagenase
Produced by the bacteria Clostridium Histiolytica, purified collagenase has been approved by the FDA for the treatment of Dupuytren's contracture. By directly injecting these lytic enzymes into the fibrotic lesions on the palmar aponeurosis, extension deficits of the digits have been shown to be significantly reduce pre and post treatment. Since the underlying pathophysiology of Dupuytren's contracture and Peyronie's disease are postulated to be similar, both involving a fibrotic plaque limiting normal function, it is logical that this method of treatment could be extrapolated to Peyronie's disease as well. A search of recent literature revealed a pilot study by Gelbard et al., in 1982 (27) , designed to investigate the feasibility and safety of collagenase in in vitro specimens. It was found that collagenase managed to successfully dissolve plaque tissue, without affecting elastic tissue, vascular smooth muscle or the myelin. This led to the authors to conclude that collagenase was potentially effective in dissolving the disease plaque, though more research is needed to establish its safety profile in vivo.
Gelbard et al. (28) went on to conduct a phase I prospective non placebo controlled study in 1985. This involved 31 patients with a mean pre-treatment penile curvature of 42°, 10 of whom had failed other treatments including intralesional corticosteroids, radiotherapy and even plaque excision and grafting. Of these 31 entrants to the study, 4 were completely unable to have coitus due to pain or penile curvature, while 14 complained of significant pain. These patients received daily injections of intralesional collagenase for 3 days and results obtained 4 weeks post treatment. In this classic series, Gelbard et al. reported good response in 20 of the 31 patients with 4 patients developing complete resolution of the penile plaques, and reduction of penile curvature in the remaining 16. Pain resolved in 13 of the 14 patients who initially complained of pain. Complications seen in this early study included mild bruising of the penile shaft and pain of the injection site. However, of significant note was the one patient who developed tunica rupture during sexual intercourse, 2 weeks post treatment. Only 1 recurrence was seen during the 9.8 months follow-up period.
These promising results led on to Gelbard's 1993 (20) double-blind, placebo-controlled trial. In this trial involving 49 men, the outcomes were significantly better in the treatment arm (P<0.07) and when his results were analyzed by disease severity, it was found that men with milder penile curvature responded better to intralesion collagenase, while those who had a penile curvature of >90° responded poorly.
Support was lent to the results of the 1985 study by Gelbard et al. (28) and by Jordan et al. in 2008 (21) , during which Jordan conducted a non-placebo controlled prospective trial of 25 patients and concluded that there was both statistically significant objective (penile curvature, penile width and plaque length) and subjective improvement at 3, 6 and 9 months after treatment with minimal treatment-related complications.
Compelled by these results, Gelbard et al. (22) published a phase IIb double-blind, randomized, placebo controlled study in 2012. In this study, Gelbard et al. recruited 147 patients and randomized them into treatment and nontreatment groups in a ratio of 3:1 with or without penile modelling (1:1). Patients were subjected to 2 intralesional injections of collagenase per cycle, 24-72 h apart. Each patient received up to 3 cycles, 6 weeks apart. Patients who were randomized into the penile modelling subgroup, received gentle penile traction after 24-72 h after each cycle, in the opposing direction of the penile curvature. The attending clinician held the penis in this position for 30 seconds before allowing it to revert to its resting position for 30 seconds. This "penile modelling cycle" was repeated for 3 times. Overall, patients who received intralesional collagenase had improvements relating to penile curvature (P<0.001) and subjective measures like symptom bother (P=0.01), intercourse discomfort (P=0.02) and intercourse constraint (P<0.001). No improvement in IIEF score was seen between the 2 groups. Further analysis revealed that the group with penile modeling after intralesional collagenase brought about a statistically significant improvement in penile curvature when compared to patients who received penile modelling with placebo (mean change: −17.5° vs. +0.6° respectively; P<0.001). Patients who received placebo and collagenase without penile modelling did not differ in the improvement of penile curvature (mean change: −13° vs. −15° respectively; P=0.9). This suggests that penile modelling is a vital part of improving penile curvature post collagenase administration, while penile modelling alone would potentially worsen the curvature, possibly by inducing trauma to the tunica and worsening the inflammatory and scarring response.
Using results from the previous study, a phase III doubleblind, randomized, placebo-controlled trial was conducted by Gelbard et al. (23) in the United States and Australia from 2010 to 2012. Affectionately named as the Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies (IMPRESS) I and II trials respectively, these two identical studies were conducted simultaneously only differing by location and numbers of patients recruited. This study actively excluded patients with a penile curvature of >90° since it has been shown in previous studies that outcomes were poor in this subgroup. A total of 832 patients were recruited (IMPRESS I: n=417, IMPRESS II: n=415). They were randomly assigned to treatment and placebo group in a ratio of 2:1. Similar to the phase IIb trial, patients in the treatment group received 2 doses of collagenase per cycle separated by 24-72 h, followed by penile modelling. The patients then went on to receive up to 3 treatment cycles separated by a rest period of 6 weeks. During the rest period, patients were instructed to perform standardized home penile modeling 3 times daily using a similar procedure. Subjects were also advised to gently attempt to straighten the penis without pain during spontaneous erection. The placebo group received similar penile modelling training and advice while receiving 2 doses of placebo injections 24 to 72 h apart per cycle, 6 weekly for a total of 4 cycles. The authors reported significant improvement in penile curvature at the end of 52 weeks in the treatment group over the control group (−17.0°±14.8°; mean reduction 34% versus −9.3°±13.6°; mean reduction 18.2%; P<0.0001). Mean change in the symptom bother domain score was also significantly improved in the treatment group (−2.8±3.8 vs. −1.8±3.5, P=0.0037). Peyronie's disease questionnaire psychological and physical symptoms (P=0.0021), IIEF overall satisfaction (P=0.0189), plaque consistency (P=0.0133) and penile length (P=0.0408) trended towards greater improvement in treated men. However, penile pain did not improve significantly between men in the placebo and treatment arm. Most treatment-related complications were mild and included penile ecchymosis, swelling and pain. Serious complications occurred in 6 patients (0.72%); 3 patients, who had either significant penile trauma or sexual intercourse within 2 weeks post collagenase injection, developed corporal rupture requiring surgery, while the remaining 3 developed penile hematoma.
Following this large scale phase III trial, collagenase injection (marketed as Xiaflex TM , Auxilium, Chesterbrook, PA) became the first FDA-approved treatment for Peyronie's disease in 2013.
Injection techniques
There is a stark difference in injection techniques between that of the administration of collagenase and the other injectable agents. Collagenase is directly injected into the primary plaque at the point of maximal penile curvature, involving only a single point of puncture to deliver the drug. This is in stark contrast to the administration of IFN 2a and verapamil, where a multiple point puncture technique delivers the drug "evenly" through the plaque. The former technique is difficult to perform as a large amount of pressure is required to inject collagenase into a plaque, which is not very distensible. On the other hand, the multi puncture technique has been criticised to have brought on clinical efficacy as a result of plaque fracture rather than the agent itself, thus complicating the interpretation of the results in previous studies.
Conclusions
The key to successfully treating a disease lies with the knowledge of its underlying pathophysiology. Although our understanding of the etiology of Peyronie's disease has come a long way, our current knowledge is probably incomplete. One has to wonder why not every patient who sustains significant penile injury develops Peyronie's disease, while others develop severe penile curvature after trivial, if any trauma at all. This draws similarities with other medical conditions such as keloid formation and Dupuytren's contracture. Perhaps a vital part of the underlying mechanism still eludes us till this day, and when found, may allow us the capability to differentiate patients, in whom the disease may spontaneously resolve, apart from those whose disease may progress. This would on one hand prevent over treatment of some patients, while preventing delays in treatment in those whose condition would only worsen over time. The focus of treatment would be to halt the acute pain and to restore sexual function by reducing penile curvature and its associated erectile dysfunction. Various treatment options have been attempted; however many have either ended up in failure or produced inconsistent results. Currently, there is no single gold standard injectable therapy and even the only FDA-approved injectable agent, collagenase, has only shown benefit in a specific subgroup of patients with the aid of penile modelling. Until a more reliable treatment emerges, some of the intralesional injectables discussed can be used to at least stabilize the plaque, and may result in some reduction of deformity with improved sexual function. This is especially so in light of the low adverse event profiles and the risk of more advanced deformity without treatment.
